Patent ID: 8147798

Claim:
A method of determining the efficacy of therapy in the treatment of amyloidosis, comprising: (A) administering to a patient in need thereof an effective amount of a compound selected from the group consisting of structures 1, 3-5, 8-16, 18, and 20-45, wherein at least one substituent moiety in the compound comprises a detectable label selected from the group consisting of 3 H, 131 I, 125 I, 123 I, 76 Br, 75 Br, 18 F, 19 F, TT C, 13 C, and 14 C: (B) imaging said patient; then (C) administering to said patient in need thereof at least one anti-amyloid agent; (D) subsequently administering to said patient in need thereof an effective amount of a compound selected from the group consisting of structures 1, 3-5, 8-16, 18, and 20-45, wherein at least one substituent moiety in the compound comprises a detectable label selected from the group consisting of 3 H, 131 I, 125 I, 123 I, 76 Br, 75 Br, 18 F, 19 F, 11 C, 13 C, and 14 C; (E imaging said patient; and (F) comparing levels of amyloid deposition in said patient before treatment with said at least one anti-amyloid agent to levels of amyloid deposition in said patient after treatment with said at least one anti-amyloid agent.